Would you change systemic therapy for metastatic melanoma on BRAF/MEK targeted therapy with excellent extracranial response, but with CNS-only progression?

Topics: Melanoma/Skin Cancer • Medical Oncology

Answer from: Medical Oncologist at Academic Institution

If a patient is on BRAF/MEK dual targeted therapy with excellent extracranial response, but with CNS progression, I would favor continuing the BRAF/MEK inhibitor therapy and considering SRS to CNS lesion(s). However, if the patient has not received prior combination IO, another option to consider wo...

Comments

Medical Oncologist at University of Virginia
Agree with the above, both options are reasonable ...

Medical Oncologist at University of Utah
How would you think about the patient with multipl...

Related Questions